Profile data is unavailable for this security.
About the company
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
- Revenue in USD (TTM)44.12m
- Net income in USD-156.25m
- Incorporated2021
- Employees274.00
- Location2Seventy Bio Inc60 Binney StreetCAMBRIDGE 02210United StatesUSA
- Phone+1 (339) 499-9300
- Fax+1 (302) 636-5454
- Websitehttps://www.2seventybio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adaptimmune Therapeutics PLC - ADR | 141.46m | -72.50m | 232.73m | 449.00 | -- | 2.42 | -- | 1.65 | -0.3452 | -0.3452 | 0.5922 | 0.3765 | 0.4256 | -- | 53.33 | 315,053.40 | -21.81 | -41.19 | -28.63 | -48.21 | -- | -- | -51.25 | -714.26 | -- | -- | 0.2058 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
Nektar Therapeutics | 93.16m | -177.08m | 235.62m | 137.00 | -- | 2.96 | -- | 2.53 | -0.9007 | -0.9007 | 0.4747 | 0.4329 | 0.2224 | 2.16 | 73.61 | 679,978.10 | -42.28 | -31.02 | -48.54 | -34.63 | 59.22 | 78.04 | -190.09 | -372.21 | 4.90 | -18.76 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
Amarin Corporation plc (ADR) | 264.78m | -33.52m | 236.74m | 275.00 | -- | 0.4292 | -- | 0.8941 | -0.082 | -0.082 | 0.6466 | 1.34 | 0.319 | 0.4395 | 2.15 | 962,832.80 | -4.04 | -4.48 | -5.79 | -6.54 | 61.29 | 75.70 | -12.66 | -8.59 | 2.01 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
Gossamer Bio Inc | 95.84m | -80.85m | 237.54m | 135.00 | -- | 2.91 | -- | 2.48 | -0.3996 | -0.3996 | 0.434 | 0.3604 | 0.3453 | -- | -- | 709,940.80 | -29.13 | -57.43 | -34.41 | -64.38 | -- | -- | -84.36 | -- | -- | -7.07 | 0.7073 | -- | -- | -- | 21.61 | -- | -- | -- |
Jasper Therapeutics Inc | 0.00 | -62.44m | 239.42m | 45.00 | -- | 2.39 | -- | -- | -5.10 | -5.10 | 0.00 | 6.64 | 0.00 | -- | -- | 0.00 | -52.45 | -- | -57.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
Mersana Therapeutics Inc | 29.94m | -104.77m | 240.44m | 123.00 | -- | 28.53 | -- | 8.03 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 244.73m | 145.00 | -- | 1.64 | -- | 3.40 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
2Seventy Bio Inc | 44.12m | -156.25m | 247.19m | 274.00 | -- | 1.05 | -- | 5.60 | -3.06 | -3.06 | 0.8417 | 4.56 | 0.0721 | -- | 1.42 | 161,021.90 | -25.54 | -- | -28.17 | -- | 66.39 | 91.76 | -354.16 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Chromadex Corp | 85.58m | -1.35m | 252.10m | 106.00 | -- | 8.16 | -- | 2.95 | -0.018 | -0.018 | 1.14 | 0.407 | 1.60 | 2.86 | 12.93 | 807,386.80 | -2.52 | -42.11 | -3.85 | -65.14 | 60.82 | 59.68 | -1.58 | -30.64 | 2.12 | -- | 0.0006 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
Solid Biosciences Inc | 0.00 | -90.69m | 254.34m | 88.00 | -- | 1.31 | -- | -- | -3.30 | -3.30 | 0.00 | 5.01 | 0.00 | -- | -- | 0.00 | -41.63 | -49.99 | -44.77 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0076 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
Design Therapeutics Inc | 0.00 | -50.53m | 257.91m | 57.00 | -- | 0.9872 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Poseida Therapeutics Inc | 88.46m | -112.77m | 258.34m | 337.00 | -- | 4.25 | -- | 2.92 | -1.19 | -1.19 | 0.9296 | 0.6265 | 0.3051 | -- | 7.27 | 268,066.70 | -38.89 | -40.70 | -52.75 | -47.72 | -- | -- | -127.48 | -233.49 | -- | -13.14 | 0.4916 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
Instil Bio Inc | 0.00 | -119.58m | 259.83m | 49.00 | -- | 1.33 | -- | -- | -18.39 | -18.39 | 0.00 | 29.98 | 0.00 | -- | -- | 0.00 | -34.04 | -- | -35.48 | -- | -- | -- | -- | -- | -- | -- | 0.2958 | -- | -- | -- | 30.06 | -- | -- | -- |
Vanda Pharmaceuticals Inc. | 182.02m | -10.93m | 262.30m | 203.00 | -- | 0.4835 | -- | 1.44 | -0.1886 | -0.1886 | 3.15 | 9.31 | 0.2815 | 9.96 | 4.82 | 896,660.10 | -1.69 | 6.61 | -1.97 | 7.62 | 93.03 | 90.55 | -6.00 | 15.18 | 4.67 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
Holder | Shares | % Held |
---|---|---|
Kynam Capital Management LPas of 31 Mar 2024 | 5.95m | 11.58% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 4.19m | 8.15% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 4.15m | 8.08% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 3.69m | 7.18% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.51m | 6.83% |
Baker Bros. Advisors LPas of 31 Mar 2024 | 2.50m | 4.86% |
Madison Avenue Partners LPas of 31 Mar 2024 | 2.43m | 4.73% |
Casdin Capital LLCas of 10 Jun 2024 | 2.02m | 3.94% |
Healthcare of Ontario Pension Planas of 31 Mar 2024 | 1.74m | 3.38% |
Point72 Asset Management LPas of 31 Mar 2024 | 1.61m | 3.14% |